trending Market Intelligence /marketintelligence/en/news-insights/trending/JQfhtWWwYN1LjqrNICLjJA2 content esgSubNav
In This List

Immunomedics secures patent for investigational cancer treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Immunomedics secures patent for investigational cancer treatment

Immunomedics Inc. secured patent coverage for its IMMU-140 cancer treatment in the U.S.

The protection will last until July 2033 and will cover the use of IMMU-140 in multiple cancer types, including melanoma, kidney or liver.

IMMU-140 is an investigational drug that is currently under development.